SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer-Reference-Cited by-同舟云学术

SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer

Published:2017-12 Issue:12 Volume:28 Page:3028-3036
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Soria J.-C.,Fülöp A.,Maciel C.,Fischer J.R.,Girotto G.,Lago S.,Smit E.,Ostoros G.,Eberhardt W.E.E.,Lishkovska P.,Lovick S.,Mariani G.,McKeown A.,Kilgour E.,Smith P.,Bowen K.,Kohlmann A.,Carlile D.J.,Jänne P.A.

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/12/3028/24169187/mdx628.pdf

Reference19 articles.

1. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor;Yeh;Clin Cancer Res,2007

2. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer;Banerji;Clin Cancer Res,2010

3. Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice;Denton;Cancer Chemother Pharmacol,2011